Pfizer reported stronger-than-expected third-quarter results, with revenue reaching $16.58 billion, above the anticipated $15.87 billion. Adjusted earnings per share (EPS) were $0.87, exceeding the expected $0.73. The company projects full-year revenue to be between $62 billion and $64 billion, with adjusted EPS ranging from $2.95 to $3.05. Revenue from in-line and acquired products increased by 32% year-over-year.